药品详细
Nabumetone (萘丁美酮 )
化学结构式图
中文名
萘丁美酮
英文名
Nabumetone
分子式
Not Available
化学名
4-(6-methoxynaphthalen-2-yl)butan-2-one
分子量
Average: 228.2863
Monoisotopic: 228.115029756
Monoisotopic: 228.115029756
CAS号
42924-53-8
ATC分类
M01A 未知
药物类型
small molecule
阶段
商品名
Arthaxan (SmithKline Beecham (Germany; discontinued));Balmox (Beecham (Portugal), Meda (Switzerland));Consolan;Dolsinal (Ferrer (Spain; discontinued));Flambate;Listran (Uriach (Spain));Mebutan (Meda (Netherlands));Nabuser (Geymonat (Italy));Prodac;Relafen (GlaxoSmithKline (Canada, USA; discontinued));Relif (Meda (Spain));Relifen (Sanwa (Japan), GSK (South Africa));Relifex (Meda (Czeck Republic, Denmark, Finland, Germany, Greece, Hungary, Ireland, Italy, Norway, Sweden, United Kingdom), GSK (Israel, Mexico, Poland, Thailand, Turkey), SmithKline Beecham (Philippines));Unimetone;
同义名
Nabumetona;Nabumetonum [INN-Latin];
基本介绍
Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid family (which includes diclofenac). Marketed under the brand name Relafen, it has been shown to have a slightly lower risk of gastrointestinal side effects than most other non-selective NSAIDs.
生产厂家
- Actavis elizabeth llc
- Copley pharmaceutical inc
- Dr reddys laboratories ltd
- Invagen pharmaceuticals inc
- Matrix laboratories ltd
- Par pharmaceutical
- Sandoz inc
- Smithkline beecham corp dba glaxosmithkline
- Teva pharmaceuticals usa inc
封装厂家
参考
Synthesis Reference | Not Available |
General Reference | Not Available |
剂型
Form | Route | Strength |
---|---|---|
Tablet, film coated | Oral | 500 mg |
Tablet, film coated | Oral | 750 mg |
规格
Unit description | Cost | Unit |
---|---|---|
Relafen 750 mg tablet | 2.91 USD | tablet |
Relafen 500 mg tablet | 2.82 USD | tablet |
Nabumetone 750 mg tablet | 1.56 USD | tablet |
Nabumetone 500 mg tablet | 1.32 USD | tablet |
Apo-Nabumetone 500 mg Tablet | 0.39 USD | tablet |
Mylan-Nabumetone 500 mg Tablet | 0.39 USD | tablet |
Novo-Nabumetone 500 mg Tablet | 0.39 USD | tablet |
化合物类型
Type | small molecule |
Classes |
|
Substructures |
|
适应症
ANTIINFLAMMATORY AND ANTIRHEUMATIC 消炎抗风湿;
药理
Indication | For acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis. | ||||||
Pharmacodynamics | Nabumetone is a naphthylalkanone. Is is a non-selective prostaglandin G/H synthase (a.k.a. cyclooxygenase or COX) inhibitor that acts on both prostaglandin G/H synthase 1 and 2 (COX-1 and -2). Prostaglandin G/H synthase catalyzes the conversion of arachidonic acid to prostaglandin G2 and prostaglandin G2 to prostaglandin H2. Prostaglandin H2 is the precursor to a number of prostaglandins involved in fever, pain, swelling, inflammation, and platelet aggregation. The parent compound is a prodrug that undergoes hepatic biotransformation to the active compound, 6-methoxy-2-naphthylacetic acid (6MNA). The analgesic, antipyretic and anti-inflammatory effects of NSAIDs occur as a result of decreased prostaglandin synthesis. | ||||||
Mechanism of action | The parent compound is a prodrug, which undergoes hepatic biotransformation to the active component, 6-methoxy-2-naphthylacetic acid (6MNA), that is a potent inhibitor of prostaglandin synthesis, most likely through binding to the COX-2 and COX-1 receptors. | ||||||
Absorption | Well absorbed from the gastrointestinal tract. Coadministration of food increases the rate of absorption and subsequent appearance of 6MNA (the active metabolite) in the plasma but does not affect the extent of conversion of nabumetone into 6MNA. | ||||||
Volume of distribution | Not Available | ||||||
Protein binding | The active metabolite, 6MNA, is more than 99% bound to plasma proteins. | ||||||
Metabolism |
Undergoes rapid biotransformation to the principal active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Approximately 35% of a 1000 mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine. |
||||||
Route of elimination | Approximately 35% of a 1000 mg oral dose of nabumetone is converted to 6MNA and 50% is converted into unidentified metabolites which are subsequently excreted in the urine. | ||||||
Half life | Approximately 23 hours for the active metabolite, 6MNA. Increased in patients with renal insufficiency. | ||||||
Clearance |
|
||||||
Toxicity | The one overdose occurred in a 17-year-old female patient who had a history of abdominal pain and was hospitalized for increased abdominal pain following ingestion of 30 nabumetone tablets (15 grams total). Stools were negative for occult blood and there was no fall in serum hemoglobin concentration. The patient had no other symptoms. | ||||||
Affected organisms |
|
||||||
Pathways |
|
理化性质
Properties | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
State | solid | ||||||||||||||||||||||||||||||||||||
Melting point | Not Available | ||||||||||||||||||||||||||||||||||||
Experimental Properties |
|
||||||||||||||||||||||||||||||||||||
Predicted Properties |
|
药物相互作用
Drug | Interaction |
---|---|
Acenocoumarol | The NSAID, nabumetone, may increase the anticoagulant effect of acenocoumarol. |
Alendronate | Increased risk of gastric toxicity |
Anisindione | The NSAID, nabumetone, may increase the anticoagulant effect anisindione. |
Cyclosporine | Monitor for nephrotoxicity |
Dicumarol | The NSAID, nabumetone, may increase the anticoagulant effect of dicumarol. |
Ginkgo biloba | Additive anticoagulant/antiplatelet effects may increase bleed risk. Concomitant therapy should be avoided. |
Methotrexate | The NSAID, nabumetone, may decrease the renal excretion of methotrexate. Increased risk of methotrexate toxicity. |
Telmisartan | Concomitant use of Telmisartan and Nabumetone may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. |
Timolol | The NSAID, Nabumetone, may antagonize the antihypertensive effect of Timolol. |
Trandolapril | The NSAID, Nabumetone, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Nabumetone is initiated, discontinued or dose changed. |
Treprostinil | The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Nabumetone. Monitor for increased bleeding during concomitant thearpy. |
Warfarin | The antiplatelet effects of nabumetone may increase the bleed risk associated with warfarin. Consider alternate therapy or monitor for signs and symptoms of bleeding during concomitant therapy. |
食物相互作用
- Avoid alcohol.
- Take with food for faster absorption.